Vitamin D and antiphospholipid syndrome: A retrospective cohort study and meta-analysis.

What It Covers

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a meta-analysis.

(a) To determine serum 25-OH vitamin D (vitD) levels in primary antiphospholipid syndrome (APS) and to compare them with patients with positive antiphospholipid serology who do not meet clinical criteria for APS, and with healthy controls.

(b) To analyze the association of vitD levels with both the clinical manifestations and the immunological profile of patients with primary APS.

(c) To perform a meta-analysis evaluating potential differences in serum vitD levels between APS and controls as well as the frequency of vitD deficiency in APS patients.

Who the Included Studies Covered

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Retrospective study including 74 patients with primary APS, 54 with positive antiphospholipid (aPL) serology not meeting clinical criteria for APS, and 215 healthy controls.

Meta-analysis included four case-control studies (325 primary APS patients and 507 controls) and was conducted by fitting random effects models and checked for heterogeneity.

How the Review Was Done

The researchers considered 30 and 10ng/ml as the thresholds for vitD insufficiency and deficiency, respectively.

What Was Measured

Topics PubMed links to this paper include Antibodies, Antiphospholipid, Antiphospholipid Syndrome, Case-Control Studies and Vitamin D.

The authors tagged it with the keywords Meta-analysis.

What This Means in Plain Language

This is a meta-analysis of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Seminars in arthritis and rheumatism), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.